A New Contender in Weight Loss: Bofanglutide Outperforms Ozempic in Clinical Trials
A significant breakthrough in weight loss and metabolic health has emerged this week: a novel GLP-1 injection named bofanglutide. Developed by Gan & Lee Pharmaceuticals in Beijing, China, bofanglutide has showcased impressive results in a phase 2b randomized clinical trial. The game-changer? It only needs to be administered once every two weeks.
In contrast to leading GLP-1 medications like Ozempic and Wegovy that necessitate weekly injections, bofanglutide delivers the same benefits but on a biweekly schedule. This could be a revolutionary advantage for patients who find frequent injections challenging. The trial comprised 272 adults with type 2 diabetes from 37 sites across China, with an average participant age of 50.8. HbA1c levels were monitored over a 24-week follow-up period.
The results were indeed remarkable. All bofanglutide groups demonstrated significant reductions in blood sugar levels, in some instances even slightly surpassing those achieved with semaglutide. Participants also reported significant weight loss and enhancements in cardiometabolic risk factors. This positions bofanglutide as a promising next-generation contender in the rapidly growing GLP-1 drug race.
With the global demand for effective, convenient weight management solutions on the rise, this biweekly formulation could signify a major advancement in patient compliance and treatment outcomes. Experts are keenly monitoring as the drug progresses towards later-stage trials.
Source: Healthline — New Biweekly GLP-1 Shot Lowers Blood Sugar, Supports Weight Loss